Certainly with respect to cancers of the lung, prostate and colon, which rely in part upon EGFR signaling for tumor growth and survival, dual targeting of IGF-1R and EGFR has garnered much interest, given the fact that reciprocal inhibition of one RTK in epithelial cancers often enhances expression of the other. Here, EGFR is linked to neoplasm.